Table 1 Identification of M1 and M2 macrophage markers with flow cytometry
From: Delivery of cisplatin and resiquimod in nanomicelles for the chemoimmunotherapy of ovarian cancer
Group | CD16-positive expression rate | CD163-positive expression rate |
|---|---|---|
Control group | 15% | 72% |
CDDP | 16% | 70% |
Resiquimod | 35% | 19% |
IFN-γ + LPS | 48% | 25% |
CDDP/resiquimod/PLG-g-mPEG | 65%① | 15%① |